BioArctic AB (publ) Market Cap ($2.56 Billion)
Market Cap & Net Worth: BioArctic AB (publ) (BIOA-B)
BioArctic AB (publ) market cap. BioArctic AB (publ) (ST:BIOA-B) has a market capitalization of $2.56 Billion (Skr23.75 Billion) as of October 31, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #5229 globally and #71 in its home market, demonstrating a 6.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioArctic AB (publ)'s stock price Skr319.40 by its total outstanding shares 74344689 (74.34 Million).
BioArctic AB (publ) Market Cap History (2017–2026)
BioArctic AB (publ) market cap history from 2017 to 2026. Data shows growth from $203.88 Million to $2.56 Billion (30.64% CAGR). Check latest BioArctic AB (publ) stock price today for real-time trading data and today's change.
BioArctic AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioArctic AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see BIOA-B operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.24x
BioArctic AB (publ)'s market cap is 1.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.43x
BioArctic AB (publ)'s market cap is 2.43 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $203.88 Million | $140.71 Million | $15.16 Million | 1.45x | 13.45x |
| 2018 | $643.02 Million | $713.97 Million | $381.60 Million | 0.90x | 1.69x |
| 2019 | $759.26 Million | $281.77 Million | $88.47 Million | 2.69x | 8.58x |
| 2020 | $763.26 Million | $62.35 Million | -$68.52 Million | 12.24x | N/A |
| 2021 | $953.68 Million | $23.15 Million | -$119.79 Million | 41.20x | N/A |
| 2022 | $2.18 Billion | $228.29 Million | -$11.18 Million | 9.53x | N/A |
| 2023 | $2.14 Billion | $616.00 Million | $229.25 Million | 3.48x | 9.35x |
| 2024 | $1.60 Billion | $257.35 Million | -$177.08 Million | 6.20x | N/A |
| 2025 | $2.49 Billion | $2.00 Billion | $1.02 Billion | 1.24x | 2.43x |
Competitor Companies of BIOA-B by Market Capitalization
Companies near BioArctic AB (publ) in the global market cap rankings as of October 31, 2026. See BioArctic AB (publ) (BIOA-B) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to BioArctic AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of BioArctic AB (publ) (2017–2026)
Market capitalization of BioArctic AB (publ) from 2017 to today. Between 2017 and today, BioArctic AB (publ)'s market cap moved from $203.88 Million to $ 2.56 Billion, with a yearly change of 30.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr2.56 Billion | +2.77% |
| 2025 | Skr2.49 Billion | +55.79% |
| 2024 | Skr1.60 Billion | -25.50% |
| 2023 | Skr2.14 Billion | -1.54% |
| 2022 | Skr2.18 Billion | +128.19% |
| 2021 | Skr953.68 Million | +24.95% |
| 2020 | Skr763.26 Million | +0.53% |
| 2019 | Skr759.26 Million | +18.08% |
| 2018 | Skr643.02 Million | +215.39% |
| 2017 | Skr203.88 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of BioArctic AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.56 Billion USD |
| MoneyControl | $2.56 Billion USD |
| MarketWatch | $2.56 Billion USD |
| marketcap.company | $2.56 Billion USD |
| Reuters | $2.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more